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Over the past few years, the role of intestinal alkaline phosphatase (IAP) as a crucialmucosal defence factor essential formaintaining
gut homeostasis has been established. IAP is an important apical brush border enzyme expressed throughout the gastrointestinal
tract and secreted both into the intestinal lumen and into the bloodstream. IAP exerts its effects through dephosphorylation of
proinflammatory molecules including lipopolysaccharide (LPS), flagellin, and adenosine triphosphate (ATP) released from cells
during stressful events. Diminished activity of IAP could increase the risk of disease through changes in the microbiome, intestinal
inflammation, and intestinal permeability. Exogenous IAP exerts a protective effect against intestinal and systemic inflammation
in a variety of diseases and represents a potential therapeutic agent in diseases driven by gut barrier dysfunction such as IBD.
The intestinal protective mechanisms are impaired in IBD patients due to lower synthesis and activity of endogenous IAP, but
the pathomechanism of this enzyme deficiency remains unclear. IAP has been safely administered to humans and the human
recombinant form of IAP has been developed.This review was designed to provide an update in recent research on the involvement
of IAP in intestinal inflammatory processes with focus on IBD in experimental animal models and human patients.
1. Introduction
Alkaline phosphatase (AP) is a superfamily of metalloen-
zymes known to catalyse the hydrolytic removal of phosphate
from a variety of molecules [1]. The mammalian AP family
consists of several isozymes which can be classified as tissue-
nonspecific APs (TNAP) expressed in bone, liver, and kidney
and tissue-specific APs, intestinal, placental, and germ cell
type of the enzyme [1, 2]. Intestinal alkaline phosphatase
(IAP) exhibits its biological activity in alkaline conditions
with highest activity at a pH 9.7 [1, 3–5]. IAP is expressed
throughout the gastrointestinal tract with highest expression
in duodenum and to a much lesser extent in the jejunum,
ileum, and colon, but it has also been detected in the stool.
Interestingly, the expression of IAP is almost absent in the
healthy stomach, but the TNAP isoform was identified at
low levels in the healthy colon [6]. IAP present in the apical
microvilli of the brush border of enterocytes and secreted
into both the intestinal lumen and the bloodstream has
been considered as gut mucosal defence factor essential for
maintaining gut homeostasis [3–5]. Fawley and Gourlay [7]
reviewing data from several animal and human studies have
demonstrated that exogenous IAP exerts the protective effect
against intestinal and systemic inflammation in a variety of
diseases. Furthermore, the human recombinant IAP is at
present undergoing phase 2 of clinical trial clearly suggesting
an importance of this enzyme in the therapy of lower GI
disorders [7]. The IAP is expressed throughout the intestine
with the highest expression in the duodenum, whereas its
phosphatase activity is highest in the terminal ileum [7]. The
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IAP has been shown to inhibit the activation of NF-𝜅B and its
translocation into the nucleus, thus preventing the expression
of proinflammatory cytokines [7].
2. Mechanisms of Action of IAP
Among major functions of IAP in GI tract the most impor-
tant are the regulation of bicarbonate secretion and pH at
duodenal surface, the modulation of intestinal long-chain
fatty acids (LCFA) absorption, and the detoxification of
endotoxin lipopolysaccharide (LPS) leading to local intestinal
and systemic anti-inflammatory effects. These actions of IAP
are critical for the maintenance of the normal homeostasis
of gut microbiota and the inhibition of their translocation
across mucosal barrier of the gut [4, 10]. Of those mentioned,
the ability of IAP to inactivate LPS seems to be particularly
important. LPS is a major component of the outer membrane
of Gram-negative bacteria [11] which compose a substantial
part of the mammalian intestinal microbiota [2]. LPS could
bind to LPS-binding protein (LBP) and the LBP-LPS complex
is transferred to membrane-bound or soluble CD14, thereby
enabling interactions with toll-like receptors (TLRs) on cell
membranes [12]. Upon activation by LPS, toll-like receptor
4 (TLR4) initiates a signalling cascade leading to the release
of proinflammatory cytokines as tumour necrosis factor-
𝛼 (TNF-𝛼), interleukin- (IL-) 1, IL-6, IL-8, and IL-12 [13].
Endotoxemia resulting from the abundance of LPS in the
blood stream can lead to a septic shock, if the immune
response is severely pronounced but at lower levels of immu-
nity, it can also stimulatemild chronic inflammatory response
associated with chronic inflammatory diseases [14].
These effects of LPS are mainly mediated by the lipid
A moiety of LPS, which permits its binding to the toll-
like receptor 4 (TLR4) and activate two distinct pathways,
namely, myeloid differentiating factor 88- (MyD88-) depen-
dent andMyD88-independent pathway. Initiation ofMyD88-
dependent pathway could lead to activation of nuclear factor-
𝜅B (NF-𝜅B) and release of several proinflammatory cytokines
[15].
The toxicmoiety of lipid A in LPS contains two phosphate
groups that are essential for its biological action [16]. IAP
plays a vital role in promoting mucosal tolerance to gut
bacteria via dephosphorylation of LPS and, in general, APs
have been shown to remove lipid A phosphate of the LPS
[17–19]. The two phosphate groups of the LPS lipid A moiety
support stable binding to the receptor complex, and the
dephosphorylation of lipid A leads to the amelioration of
inflammatory activity of LPS [20]. IAP has been shown to
inhibit MyD88-dependent pathway by preventing of the acti-
vation of TLR4, thus dampening the activation of NF-𝜅B and
ultimately repressing the downstream of TLR-4-dependent
and inflammatory cascades [3, 5, 15]. Consequently, the
dephosphorylated LPS due to IAP is no longer able to cause
TLR4 stimulation and may even block its binding to receptor
acting as an antagonist of TLR-4 receptors [4, 10, 21]. The
LPS interaction with the IAP has been supported by the
fact that the administration of exogenous IAP attenuated
LPS-mediated toxicity [22, 23] (Figure 1). Another poten-
tial IAP targets could be unmethylated cytosine-guanosine
dinucleotides (CpG, a component of bacterial DNA) and
flagellin (a protein found in bacterial flagella) both of which
known to induce host inflammatory responses [24]. It has
been demonstrated that inhibition of endogenous IAP by L-
phenylalanine increases serum LPS levels [24].
3. IAP and the Intestinal Microbiota
The gastrointestinal tract contains an enormous number of
microorganisms, collectively known as the gut microbiota.
The intestinal microbiota plays a significant role in main-
taining human health and dysbiosis defined as pathological
imbalance in the gut microbiota. The alteration in intestinal
microbiota has been implicated in the pathogenesis of var-
ious diseases including inflammatory bowel disease (IBD),
antibiotic-associated diarrhoea (AAD), Clostridium difficile-
associated disease (CDAD), metabolic syndrome, obesity,
and cancer [30, 31].
It has been suggested that IAP can directly regulate main-
tenance of normal gut microbial homeostasis. Bates et al. [32]
proposed that IAP could play an essential role in promoting
mucosal tolerance to the resident gut bacteria by prevent-
ing LPS-mediated inflammatory response. In IAP-knockout
mice, increased bacterial translocation to mesenteric lymph
nodes was observed when the intestine was subjected to a
ischemic injury [21]. Malo et al. [31] have demonstrated that
IAP-KOmice exhibitedmuch less of different types of aerobic
and anaerobic bacteria than the wild-type mice and that oral
supplementation of IAP reversed this abnormality.They have
concluded that IAP is involved in the maintenance of normal
gut microbial homeostasis and suggested the therapeutic
potential of this enzyme [31]. In another study by the same
group of investigators, a mechanism by which IAP may posi-
tively regulate the intestinal microbiome was identified, inac-
tivation (dephosphorylation) of phosphorylated nucleotides
in the intestinal lumen [8].They observed that IAP-knockout
mice exhibited more ATP in their luminal contents than the
wild-type mice [32]. Moreover, the exogenous IAP was able
to reverse the ATP-mediated inhibition of bacterial growth
[8] (Figure 1). It was suggested that IAP stimulates bacterial
growth in the intestinal lumen and luminal ATP inhibits
mainly Gram-positive bacteria. This inhibition could be
reversed by exogenous IAP,which dephosphorylates freeATP
[9]. The administration of exogenous IAP in mice showed
a decrease in severity rates of Salmonella typhimurium and
Clostridium difficile-associated disease activity with IAP’s
ability to rapidly restore the regular gut microbiota [33].
4. Diet and IAP
Diet has been regarded as an important factor in many
chronic inflammatory diseases such as IBD ormetabolic syn-
drome. That is why an assumption aroused that IAP expres-
sion and activity as for other intestinal enzymes can be reg-
ulated by diet. For instance, Goldberg et al. [21] have shown
that the IAP expression and LPS-dephosphorylating activity
were dramatically decreased after two days of fasting in mice
maintained at enteral feeding [21]. They suggested that the
IAP silencing that occurs with starvationmay, at least in part,


















Figure 1: Hypothetical model depicting the mechanism by which a brush border enzyme intestinal alkaline phosphatase (IAP) affects the
intestinal microbiota, the release of bacterial LPS-induced inflammation, and the luminal content of ATP inhibiting the commensal bacteria
of different origin. Under inflammation, the proinflammatory cytokines can inhibit the content and activity of protective IAP. The IAP can
dephosphorylate bacterial LPS which leads to LPS detoxification, thus preventing downstream activation of immunocytes and the subsequent
inflammatory responses. The IAP can inhibit luminal ATP by the mechanism involving the ATP dephosphorylation.This enzyme was found
to exert an inhibitory effect on the growth and survival of a wide spectrum of bacteria and to prevent bacteria translocation from intestinal
lumen into bloodstream.The mechanisms illustrated in this figure which are described in the text were inspired by [8, 9] cited in this review.
explain the impaired gut mucosal defence seen in critically
ill patients. Clinical studies have documented the protective
effects of trophic enteral feeding in patients who were unable
to tolerate a normal oral diet, but the underlying mechanism
of this barrier dysfunction in these patients has not been so
far explained [21]. Some controversy exists on the effect of
high-fat diet (HFD) with respect to IAP activity. Alpers et al.
[3] have shown an increase in IAP secretion in response to
HFD possibly as a consequence of intestinal membrane self-
defence protective mechanisms that can oppose deleterious
effect resulting from an enhancement in microbial LPS
levels [34, 35]. However, in another study, HFD resulted
in a downregulation of IAP expression [35]. A possible
explanation could be that this downregulation of IAP is due
to the enhanced concentration of the fat in HFD diet known
to affect the IAP regulation in intestine of these animals [35].
5. IAP and Inflammatory Chronic Diseases
Decreased IAP expression has been implicated in many
chronic inflammatory diseases such as inflammatory bowel
disease (IBD), celiac disease, metabolic syndrome, and obe-
sity.
5.1. IBD. Recent evidence indicates that IAP may have a
therapeutic role in IBD without the risk of harmful effects
associated with currently accepted therapies. IBDs are a
heterogeneous group of disorders exhibiting two major
forms, Crohn’s disease (CD) and ulcerative colitis (UC),
characterized by a cyclic nature, alternating between active
and quiescent states [36]. The IBD aetiology is still relatively
unknown and the current concept is that a combination of
environmental agents and a dysfunctional mucosal immune
system in genetically susceptible individuals could lead to
the development of this disease [37–39]. The incidence rates
and prevalence of IBD over the past 50 years have increased
remarkably in countries that have adapted a “westernized”
lifestyle [40, 41] characterized by serious modifications in
dietary habits and decreased physical activity. The composi-
tion of the gut microbiota is thought to be a critical factor
in the development of IBD and an association between diet
and the composition of the human microbiome has been
demonstrated [42–45]. Dietary patterns characteristic for
industrialized developed countriesmight promote a dysbiosis
in genetically predisposed subjects [45]. In an experimen-
tal mouse model, the chronic high-fat diets have altered
the composition of gut microbiota leading to a “dysbiotic”
microbiome and an increase in the incorporation into chy-
lomicrons of LPS. This effect not only compromised the gut
mucosal integrity but also promoted the mucosal entry of
pathogenic agents from the intestinal lumen into the blood-
stream [46, 47]. Deficiencies in response mechanisms such
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Table 1: Characteristics of animal studies examining potential role of IAP in experimental colitis.
Reference Study type Study outcome
Goldberg et al., 2008 [21] IAP-knockout mice (C57BL/6 background)
In mice with intestinal barrier dysfunction induced by
ischemia the IAP-knockout mice had increased severity
of intestinal inflammation and increased bacterial
translocation as compared to wild-type mice.
Mart́ınez-Moya et al. 2012
[6] Wistar rats
IAP was given to rats by the oral or intrarectal route and
have beneficial effects on experimental trinitrobenzene
sulfonic acid (TNBS) and dextran sulfate sodium (DSS)
model of rat colitis, which includes protection against
bacterial translocation. Treatment with intrarectal IAP
was more effective than oral route.
Tuin et al., 2009 [19] Sprague-DawleyRats
Orally administered IAP caused a significant reduction
of inflammation in rat model of DSS -induced colitis in
rats.
Bol-Schoenmakers et al.,
2010 [25] C57BL/6J mice
In DSS induced colitis, the oral IAP administration
exerts a beneficial effect against severe intestinal
epithelial damage. Rectal administration of LPS into a
moderate inflamed colon did not aggravate
inflammation.
Ramasamy et al., 2011 [26]
IAP-KO and
WT C57BL/6 mice
WASP-KO (129 SvEv background) mice
In two independent mouse models of chronic colitis:
DSS-induced mouse colitis model in wild type mice
and IAP knock out mice and the irradiation induced
WASP-KO colitis, orally administered IAP significantly
attenuated inflammation in both, IAP-knockout and
wild-type mice in the chronic colitis model.
Lee et al., 2014 [27] IL-10−/−mice (C57BL/6 background)
In piroxicam-induced IL-10 knockout mice, the
significant reduction of experimental colitis severity
was observed after oral administration of IAP.
as IAP activity against bacterial products, in particular LPS,
have been shown to be an important factor underlying IBD
pathogenesis [48, 49]. Dysbiosis and decreased complexity
of the gut microbial ecosystem are common features in IBD
patients [50]. IBD patients have a significantly higher TLR4
expression when compared to healthy controls [51, 52]. Cario
and Podolsky have collected small intestinal and colonic
biopsy specimens from IBD patients and observed that TLR4
was strongly upregulated in intestinal epithelium of UC and
CDpatients [51]. Similarly, the increased levels of TLR4 in the
inflamed colonicmucosa of childrenwith IBDwere observed.
Interestingly, the TLR4 mRNA levels were similar to controls
in the noninflamed colonicmucosa of childrenwith IBD [52].
Furthermore, UC or CD patients have demonstrated a
low IAP activity compared with normal healthy controls [19,
53]. Consequently, the impairment of the intestinal protective
mechanismobserved in patientswith IBDhas been attributed
to the lower intestinal synthesis and activity of endogenous
IAP, but the pathomechanismof this disorderwith the respect
to IAP deficiency has not been fully explored [19].
5.1.1. Animal Studies. Several studies have examined the role
of IAP in experimental colitis (Table 1). In IAP-knockout
(IAP-KO)mice with ischemia-induced intestinal barrier dys-
function, the increased intestinal inflammation was observed
possibly due to promotion of the bacterial translocation
through intestinal barrier in these animals as compared to
wild-type mice [21]. In another study, Mart́ınez-Moya et al.
[6] have shown that intrarectal IAP administration prevented
bacterial translocation in different models of colitis. More-
over, although the IAP-KOmice did not exhibit spontaneous
colitis, they have been shown to be more susceptible to
experimental colitis [54]. Tuin et al. [19] studied the efficacy
of orally administrated acid resistant IAP tablets on dextran
sodium sulfate- (DSS-) induced experimental colitis in rats.
They revealed a significant reduction of DSS-induced inflam-
mation with IAP therapy [19].
A similar observation was made in a mouse model of
DSS-induced colitis by another group of investigators [25].
They found the loss in body weight being significantly less
in IAP-treated mice and accompanied with reduced colon
damage as manifested in their study by a histological index
of disease activity, for example, the crypt and goblet cell loss,
intestinal oedema, and less severe neutrophils infiltration of
intestinal wall [25].
Ramasamy et al. [26] evaluated the potential therapeutic
role for orally administered IAP in two independent mouse
models of chronic colitis, namely, DSS-induced mouse colitis
model in both wild-type mice and IAP-knockout mice, and
the irradiation affected mice deficient in Wiskott-Aldrich
Syndrome Protein (WASP) colitis. They found that orally
administered IAP significantly attenuated inflammation in
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Table 2: Characteristics of studies examining the role of IAP in human IBD.
Reference Sample Outcome
Molnár et al., 2012 [28]
CD, 10 children (7 boys, 3 girls)
UC, 5 children
(3 boys, 2 girls)
Control, 10 children (5 boys, 5 girls;)
Significantly decreased IAP levels in inflamed mucosa in children
with IBD.
Tuin et al., 2009 [19]
CD, 10 (3 males, 7 females)
UC, 14 (9 males, 5 females)
Control, 14 (8 males, 6 females)
Reduced IAP mRNA expression in inflamed mucosa in adults with
UC and CD.
Lukas et al., 2010 [29] UC, 23 females
Improvement in disease activity scores,
with clinical effects being observed within 21 days and associated
with reductions in C-reactive protein and stool calprotectin.
both IAP-knockout and wild-type mice in this chronic colitis
model [26]. Lee et al. [27] have employed the piroxicam-
induced IL-10 knockout mouse model and observed the sig-
nificant reduction in the severity of experimental colitis after
oral administration of IAP.These results strongly suggest that
the lower activity of endogenous IAP is associated with an
increased severity of intestinal injury in experimental colitis
and this deleterious effect is reversed by supplementation
with exogenously administrated IAP.
5.1.2. Human Studies. In the human trial [29], the admin-
istration of IAP daily over a 7-day course to patients with
UCwas associated with a short-term improvement in disease
activity scores, and clinical beneficial effects were observed
within 21 days and associated with reductions in C-reactive
protein and stool calprotectin. It is of interest that the
treatment with exogenous IAP was well tolerated without
signs of toxicity in these patients [29], as shown in Table 2.
The hypertrophied mesenteric adipose tissue could be a
major contributor of the increased circulating proinflamma-
tory cytokines in IBD and undoubtedly play a role in the
pathogenesis and activity of this disease [55–58]. Because
of the formation of so-called “creeping fat,” this increase in
proinflammatory cytokines can be, at least in part, caused by
LPS [57, 59, 60], but the IAP administration is believed to
reduce this process.Moreover, the chronic exercise could also
contribute to the amelioration of proinflammatory cytokines
by stimulating secretion of vasodilatorymyokines fromactive
muscle units, factors that were shown to influence muscle-fat
crosstalk [61–63].
Several lines of evidence indicate that increased intestinal
permeability may have crucial role in IBD pathogenesis [64–
67]. Paracellular permeability is regulated by junctional com-
plexes: on the apical aspect, cells are linked by tight junctions
(TJ) and adherents junctions as well as by desmosomes at
the basolateral compartment. Molecular components of tight
junctions include integral membrane proteins: occludins,
claudins, and junctional adhesion molecules (JAM) as well
their scaffolding proteins (zonula occludens (ZO) proteins)
[68]. A reduced expression and redistribution of occludins,
claudins, and JAM have been reported in IBD patients [69–
71]. Guo et al. [72] demonstrated that LPS causes an increase
in intestinal tight-junction permeability in vitro and in vivo
via an intracellular mechanism involving TLR-4-dependent
upregulation of CD14 membrane expression. Liu et al. [73]
have studied the relationship between IAP deficiency and
IAP overproduction and their effect on tight-junction protein
(TJP) levels and function. They have revealed that the
pretreatment with IAP prevented the decline in junctional
protein expression, and this effect was proposed to explain
the mechanism of abrogation of the LPS-induced barrier
dysfunction in vitro. Furthermore, the administration of IAP
effectively strengthens the barrier function by a preservation
of its integrity as well as prevented the LPS-induced potential
alteration in the localization and assembly of TJ. These
observations suggest a crucial role for IAP in themaintenance
of epithelial homeostasis and barrier function. Liu et al.
[73] concluded that IAP is a chief regulator of gut mucosal
permeability and may act, at least in part, by improving TJP
levels and localization.
In excellent review, Lallès [10] suggested possible oppos-
ing effects of two AP isoforms in IBD. Based on clinical stud-
ies [19, 28, 29] and animal experiments [6, 19, 25, 26, 74, 75],
Lallès [10] observed that IAP is reduced, but TNAP is upreg-
ulated in IBD. An increased TNAP seems to originate from
both colonic epithelial cells and neutrophils. Lallès [10] sug-
gested that colonic upregulation of TNAP under inflamma-
tory conditions could represent a protective intestinal adapta-
tion against oxidative stress and progression of inflammation.
5.2. Other Chronic Diseases. The role of IAP deficiency in
the pathogenesis of metabolic syndrome has been especially
well studied. Metabolic syndrome is a cluster of conditions:
central obesity, elevated blood pressure, elevated insulin
resistance, dyslipidaemia, and fatty liver.Metabolic syndrome
leads to type 2 diabetes, atherosclerosis, and nonalcoholic
fatty liver disease [76, 77]. Previous studies revealed that the
high-fat diet (HFD) modulates gut microbiota and increases
the plasma concentration of LPS and triggers body weight
gain and diabetes [78, 79]. Moreover, endotoxemia has been
suggested to play a crucial role in pathogenesis of metabolic
syndrome [78, 79].
An essential role of LPSwas confirmed by the observation
that mice lacking TLR4, the receptor for LPS, are resistant to
HFD-induced inflammation, obesity, and insulin resistance
[80]. Mice who were made deficient of IAP exhibited an
increased intestinal permeability and high levels of LPS,
obesity, the elevated blood glucose and insulin resistance [34].
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The combined high-fat diet with IAP prevented completely
the development of metabolic syndrome [34]. In another
study, the antibiotic treatment early in life rendered mice
more susceptible to metabolic syndrome in adulthood, but
coadministration of IAPwith antibiotic prevented completely
this susceptibility to metabolic syndrome [81].
The intestinal barrier integrity is impaired in celiac
disease. This has been referred to a decrease in the IAP
expression and activity in celiac paediatric patients [81].
Furthermore, this intestinal impairment was particularly
pronounced in severe cases of the disease [82]. IAP expression
was normalised in children on gluten free diet. The same
group also found our increased mRNA and protein levels of
TLR4 in the duodenal mucosa of newly diagnosed celiac pae-
diatric patients [83]. They have suggested that uncontrolled
activation of TLR4 by LPS may induce loss of mucosal func-
tion due to an induction of a proinflammatory cascade [82].
Potential protective role of IAPwas suggested in a number
of other diseases and experimental animalmodels translating
basic research to the clinical settings. Exogenous IAP had also
beneficial effects in experimental model of necrotizing ente-
rocolitis (NEC) and was suggested to be a valuable adjunctive
treatment in NEC [18]. Ebrahimi et al. [84] have demon-
strated that peritoneal irrigation with IAP potently enhanced
survival in a mouse model of peritonitis. In recent paper,
Wang et al. [85] have shown a therapeutic effect of exogenous
IAP in mouse model of peritonitis, as manifested by the
inhibition of intestinal permeability and bacterial transloca-
tion. Exogenous IAP had also protective action in mice with
antibiotic-associated diarrhoea [86]. Furthermore, the signif-
icant fall in the activity of IAP has been documented in
duodenal biopsies taken from patients with cystic fibrosis
(CF) [87, 88]. Also inCFmousemodel, the decreased levels of
IAP and increased intestinal permeability have been observed
[89].
6. IAP and Septic Shock
Sepsis is a predominant cause of acute kidney injury (AKI)
in the intensive care unit [90] which is associated with a
high mortality and an increased risk of developing chronic
kidney failure in survivors. Two double-blind, randomized,
placebo-controlled phase II clinical trials have demonstrated
a beneficial renal effects of bovine IAP administration in
critically ill patients with sepsis-associated AKI [91, 92].
These protective effects of IAP were attributed to dephos-
phorylation of LPS and the rise in extracellular ATP [93,
94]. Administration of bovine-derived material in humans is
limited and represents many drawbacks. Therefore, a human
recombinant AP (recAP) has been recently developed [95]
and its protective effects have been confirmed in studies in
vitro and in vivo in rat model of LPS-induced AKI [96]. In a
randomized, double-blind, placebo-controlled, phase I trial
with healthy volunteers, the pharmacokinetics, safety and
tolerability of recAP was investigated and these results failed
to raise safety concerns [97].
7. Conclusion
IAP role as key regulator of inflammation, infection, and gut
microbiota mainly via dephosphorylation of LPS has been
established. Diminished activity of IAP could increase the
risk of disease through changes in the microbiome, increased
intestinal inflammation, and intestinal permeability. In light
of accumulated evidence presented in this review and the
fact that the human recombinant form of IAP (recAP) has
been developed and this recombinant form of IAP has been
safely administered to humans without any adverse effects,
we conclude that IAP may represent a potential therapeutic
agent to improve outcomes of inflammatory diseases driven
by gut barrier dysfunction such as IBD. The discovery of
recombinant form of IAP raises a hope that clinical studies
in the future can shed more light on the intriguing oppor-
tunity of a therapeutic strategy concerning the efficacy of
this enzyme in treatment of human diseases especially to
prevent dysbiosis and intestinal and systemic inflammation
frequently associated with lower GI tract disorders such as
IBD, IBS, and Clostridium difficile infection.
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[66] S. Jäger, E. F. Stange, and J. Wehkamp, “Inflammatory bowel
disease: an impaired barrier disease,” Langenbeck’s Archives of
Surgery, vol. 398, no. 1, pp. 1–12, 2013.
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